CTOs on the Move

Frequency Therapeutics

www.frequencytx.com

 
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the controlled activation of progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Dan O'Neill
Vice President of Information Technology Profile
Jeff Hrkach
Senior Vice President of Technology Development Profile

Funding

Frequency Therapeutics raised $32M on 04/17/2017
Frequency Therapeutics raised $60M on 01/07/2019
Frequency Therapeutics raised $62M on 07/23/2019
Frequency Therapeutics raised $42.3M on 07/17/2020

Similar Companies

Quad Five Materials Bio

Quad Five Materials Bio, Inc. is a Ryegate, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quincy Bioscience

Quincy Bioscience is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthScape

HealthScape is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immuneering

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering`s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering`s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.

Tranquis Therapeutics

Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide.